irf1 gene coding sequence cds (Biotechnology Information)
Structured Review

Irf1 Gene Coding Sequence Cds, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/coding+sequence+cds/pmc12799679-114-1-13?v=Biotechnology+Information
Average 86 stars, based on 1 article reviews
Images
1) Product Images from "IRF1 suppresses gastric tumorigenesis via dual PI3K/AKT-ERK pathway modulation and functional antagonism of oncogenic MX2"
Article Title: IRF1 suppresses gastric tumorigenesis via dual PI3K/AKT-ERK pathway modulation and functional antagonism of oncogenic MX2
Journal: Cellular Oncology (Dordrecht, Netherlands)
doi: 10.1007/s13402-025-01134-w
Figure Legend Snippet: Expression of IRF1 and Type I interferon pathway-related proteins in gastric cancer cells. A : Simulation of type I interferon response in gastric cancer cells by incubating with interferon, showing increased expression of interferon pathway protein IRF1. B : Protein expression in gastric cancer cells after transfection with pcDNA3.1(+) -IRF1-HA.1 C : Protein expression in gastric cancer cells after transfection with siRNA-IRF1. D : Changes in the expression of interferon pathway proteins after overexpression or inhibition of IRF1 in gastric cancer cells
Techniques Used: Expressing, Transfection, Over Expression, Inhibition
Figure Legend Snippet: Expression characteristics and clinical relevance of IRF1 in gastric cancer tissues. A : IRF1 expression is significantly higher in gastric cancer tissues compared to adjacent normal tissues ( P < 0.001). B : Paired analysis shows that IRF1 expression is significantly upregulated in gastric cancer tissues compared to matched adjacent tissues ( P = 0.002). C : Survival analysis indicates that high IRF1 expression is associated with a relatively better prognosis in gastric cancer patients (Log-rank P = 0.030). D : Representative immunohistochemistry (IHC) images showing high and low IRF1 expression in tumor tissues. E : Differential expression analysis confirms that IRF1 is significantly upregulated in tumor tissues ( P = 0.021). F : Paired analysis of tumor and adjacent normal tissues demonstrates significantly higher IRF1 expression in tumors ( P < 0.001). G : Survival analysis further supports that high IRF1 expression correlates with a better prognosis in gastric cancer patients (Log-rank P = 0.010). * P < 0.05, ** P < 0.01, *** P < 0.001, *** P < 0.0001
Techniques Used: Expressing, Immunohistochemistry, Quantitative Proteomics
Figure Legend Snippet: Effects of IRF1 expression on gastric cancer cell function. A - B : CCK8 cytotoxicity assay showing inhibition of AGS and BGC-823 cell proliferation after transfection with IRF1-HA overexpression plasmid. C - D : Transwell migration and invasion assay showing suppression of AGS and BGC-823 cell migration and invasion 48 h after transfection with IRF1-HA overexpression plasmid. E - F : CCK8 cytotoxicity assay showing promotion of AGS and BGC-823 cell proliferation after transfection with siRNA-IRF1. G - H : Transwell migration and invasion assay showing enhanced migration and invasion of AGS and BGC-823 cells 48 h after transfection with siRNA-IRF1. I : Flow cytometry apoptosis assay showing increased apoptosis in gastric cancer cells 48 h after Dox-induced IRF1 overexpression in stable cell lines. J : Changes in apoptosis-related protein expression 48 h after Dox-induced IRF1 overexpression in gastric cancer cell stable lines. K : Immunofluorescence localization experiment confirming nuclear localization of IRF1 in gastric cancer cells. Scale bar: 10 μm. * P < 0.05, ** P < 0.01, ** P < 0.001
Techniques Used: Expressing, Cell Function Assay, Cytotoxicity Assay, Inhibition, Transfection, Over Expression, Plasmid Preparation, Migration, Invasion Assay, Flow Cytometry, Apoptosis Assay, Stable Transfection, Immunofluorescence
Figure Legend Snippet: Establishment of an Inducible IRF1 expression nude mouse subcutaneous xenograft and lung metastasis model. A : In vivo experiments show that the tumor volume of the IRF1 overexpression group in nude mouse subcutaneous xenografts is significantly smaller than that of the control group (Mean ± SEM). B : Gross anatomy of subcutaneous xenograft tumors in nude mice. C : HE staining of subcutaneous xenograft tumors (tumor tissues from mouse #1 and #2). D : Immunohistochemistry (IHC) analysis of IRF1 expression in subcutaneous xenograft tumors, showing significant IRF1 overexpression in the Dox (+) group. E : Bioluminescence imaging of nude mice injected via the tail vein with BGC-IRF1-LUC cells at 0, 2, 3, and 4 weeks post-injection. F : Quantification of lung fluorescence intensity in both groups, demonstrating significantly lower fluorescence intensity in the IRF1 overexpression group compared to the control group. G : Gross anatomy of lung tissues in nude mice, showing more metastatic nodules in the control group than in the IRF1 overexpression group. H : HE staining and IRF1-specific IHC staining of lung tissues in nude mice, confirming IRF1 overexpression in the Dox-induced group. Scale bar: 100 μm. * P < 0.05, ** P < 0.01, *** P < 0.001
Techniques Used: Expressing, In Vivo, Over Expression, Control, Staining, Immunohistochemistry, Imaging, Injection, Fluorescence
Figure Legend Snippet: Exploration of IRF1-related mechanisms. A : Schematic diagram of the IRF1 protein structure; DBD: DNA binding domain; IAD: IRF-association domain. B : Validation of successful expression of the pcDNA3.1(+)-IRF1Δ1 recombinant plasmid. C : No significant changes in apoptosis-related protein expression after IRF1Δ1 overexpression. D : Overexpression of IRF1 significantly affects PI3K pathway-related proteins, whereas IRF1Δ1 overexpression shows no apparent changes. E : Bidirectional validation of the interaction between IRF1 and MX2 using HA and Flag magnetic beads. F : Immunofluorescence co-localization analysis confirming the nuclear co-expression of IRF1 and MX2
Techniques Used: Binding Assay, Biomarker Discovery, Expressing, Recombinant, Plasmid Preparation, Over Expression, Magnetic Beads, Immunofluorescence
Figure Legend Snippet: MX2-related functions in gastric cancer. A : Schematic diagram of MX2 functional domain fragments. B : Co-IP assay validating the interaction between IRF1-HA and MX2-Flag, showing that IRF1 loses interaction with MX2-FlagΔ1. C : Schematic of MX2 site-directed mutations. K131A: GTP-binding defective, unable to enter the nucleus; NLS: nuclear localization signal; BSE: bundle signaling element. D : WB validation of MX2 site-directed mutant overexpression plasmids. E : MX2 overexpression promotes AGS cell migration and invasion. F : MX2 overexpression promotes BGC-823 cell migration and invasion. G : After transfecting MX2 and its mutants into BGC-823 cells and incubating for 48 h, nuclear localization site mutations in MX2 result in the loss of its pro-migratory and pro-invasive effects. H : Immunofluorescence localization of MX2 and its mutants in gastric cancer cells. After transfection with MX2-ΔN or MX2-K131A, MX2 is retained in the cytoplasm, losing its nuclear localization ability. I : WB validation of MX2’s pro-migratory function through EMT pathway analysis. Scale bar: 10 μm. * P < 0.05, ** P < 0.01, *** P < 0.001
Techniques Used: Functional Assay, Co-Immunoprecipitation Assay, Binding Assay, Biomarker Discovery, Mutagenesis, Over Expression, Migration, Immunofluorescence, Transfection
Figure Legend Snippet: Functional model of the IRF1-MX2 protein complex
Techniques Used: Functional Assay
